Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-11-07

AUTHORS

Shiyi Yu, Xue Gong, Zhifang Ma, Meng Zhang, Ling Huang, Jun Zhang, Shuang Zhao, Tao Zhu, Zhenghong Yu, Liming Chen

ABSTRACT

PurposeEndocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ERα)-positive breast cancer. The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ERα is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism.MethodsEndocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues.ResultsWe found that in endocrine resistant breast cancer cells loss of ERα led to HDAC3 stabilization via decreased ERα-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ERα-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ERα expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ERα deficiency. The ERα-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples.ConclusionsFrom our data we conclude that the ERα-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ERα loss. More... »

PAGES

65-80

References to SciGraph publications

  • 2013-07-09. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis in BMC MOLECULAR AND CELL BIOLOGY
  • 1993-01. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-04-18. Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21Cip in ONCOGENESIS
  • 2017-03-29. Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation in CELLULAR ONCOLOGY
  • 2011-05-10. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer in BRITISH JOURNAL OF CANCER
  • 2008-09-19. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues in GENOME BIOLOGY
  • 2009-09-01. Biological determinants of endocrine resistance in breast cancer in NATURE REVIEWS CANCER
  • 2015-02-25. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression in BREAST CANCER RESEARCH
  • 2013-04-30. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression in BMC CANCER
  • 2007-08-13. Histone deacetylases and cancer in ONCOGENE
  • 2009-01-30. Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations in BMC BIOINFORMATICS
  • 2015-06-16. Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response in NATURE COMMUNICATIONS
  • 2018-12-21. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells in ONCOGENESIS
  • 2012-11-29. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond in NATURE REVIEWS CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s13402-019-00439-x

    DOI

    http://dx.doi.org/10.1007/s13402-019-00439-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1122393108

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31701491


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Acetylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Breast Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Caspase 7", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Proliferation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Resistance, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Estrogen Receptor alpha", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation, Neoplastic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histone Deacetylase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histone Deacetylases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histones", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunohistochemistry", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA Interference", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tamoxifen", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yu", 
            "givenName": "Shiyi", 
            "id": "sg:person.01230313474.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230313474.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gong", 
            "givenName": "Xue", 
            "id": "sg:person.01000607441.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000607441.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ma", 
            "givenName": "Zhifang", 
            "id": "sg:person.015756424740.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015756424740.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhang", 
            "givenName": "Meng", 
            "id": "sg:person.015431126577.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015431126577.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Huang", 
            "givenName": "Ling", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhang", 
            "givenName": "Jun", 
            "id": "sg:person.011111522421.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011111522421.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhao", 
            "givenName": "Shuang", 
            "id": "sg:person.0671022567.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671022567.52"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, 230027, Hefei, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.59053.3a", 
              "name": [
                "Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, 230027, Hefei, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhu", 
            "givenName": "Tao", 
            "id": "sg:person.016170133655.63", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016170133655.63"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yu", 
            "givenName": "Zhenghong", 
            "id": "sg:person.01275503103.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275503103.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China", 
              "id": "http://www.grid.ac/institutes/grid.260474.3", 
              "name": [
                "Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People\u2019s Republic of China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chen", 
            "givenName": "Liming", 
            "id": "sg:person.0631531742.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631531742.53"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1471-2121-14-32", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008132874", 
              "https://doi.org/10.1186/1471-2121-14-32"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3396", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031306051", 
              "https://doi.org/10.1038/nrc3396"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/gb-2008-9-9-r139", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048888907", 
              "https://doi.org/10.1186/gb-2008-9-9-r139"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/oncsis.2016.12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014215205", 
              "https://doi.org/10.1038/oncsis.2016.12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-13-215", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004045936", 
              "https://doi.org/10.1186/1471-2407-13-215"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms8390", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019679615", 
              "https://doi.org/10.1038/ncomms8390"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00665801", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030257873", 
              "https://doi.org/10.1007/bf00665801"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2713", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018166274", 
              "https://doi.org/10.1038/nrc2713"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13058-015-0533-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049624305", 
              "https://doi.org/10.1186/s13058-015-0533-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41389-018-0107-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1110807996", 
              "https://doi.org/10.1038/s41389-018-0107-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1210610", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023418889", 
              "https://doi.org/10.1038/sj.onc.1210610"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2105-10-s1-s24", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013766507", 
              "https://doi.org/10.1186/1471-2105-10-s1-s24"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13402-017-0322-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084037136", 
              "https://doi.org/10.1007/s13402-017-0322-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2011.156", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040609384", 
              "https://doi.org/10.1038/bjc.2011.156"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-11-07", 
        "datePublishedReg": "2019-11-07", 
        "description": "PurposeEndocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ER\u03b1)-positive breast cancer. The cure rate of patients with ER\u03b1-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ER\u03b1 is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism.MethodsEndocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues.ResultsWe found that in endocrine resistant breast cancer cells loss of ER\u03b1 led to HDAC3 stabilization via decreased ER\u03b1-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ER\u03b1-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ER\u03b1 expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ER\u03b1 deficiency. The ER\u03b1-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples.ConclusionsFrom our data we conclude that the ER\u03b1-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ER\u03b1 loss.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s13402-019-00439-x", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.8370866", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.8351548", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1372011", 
            "issn": [
              "2211-3428", 
              "2211-3436"
            ], 
            "name": "Cellular Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "43"
          }
        ], 
        "keywords": [
          "endocrine-resistant breast cancer cells", 
          "resistant breast cancer cells", 
          "breast cancer cells", 
          "endocrine resistance", 
          "breast cancer", 
          "cancer cells", 
          "resistant breast cancer cell lines", 
          "endocrine-resistant breast cancer", 
          "primary breast cancer tissues", 
          "ER\u03b1-positive breast cancer", 
          "cancer cell loss", 
          "protein expression", 
          "resistant breast cancer", 
          "positive breast cancer", 
          "loss of ER\u03b1", 
          "pan-HDAC inhibitors", 
          "breast cancer cell lines", 
          "breast cancer tissues", 
          "inhibition of HDAC3", 
          "breast cancer samples", 
          "colony forming assays", 
          "PurposeEndocrine therapy", 
          "ER\u03b1 deficiency", 
          "cancer cell lines", 
          "ER\u03b1 expression", 
          "cure rate", 
          "estrogen receptor", 
          "therapeutic target", 
          "HDAC3 inhibition", 
          "ER\u03b1 loss", 
          "cancer tissues", 
          "CCK-8", 
          "cell loss", 
          "mRNA expression", 
          "Western blotting", 
          "cancer samples", 
          "proliferative ability", 
          "cancer", 
          "qRT-PCR", 
          "acetylation status", 
          "cell lines", 
          "ER\u03b1", 
          "molecular mechanisms", 
          "Recent studies", 
          "cells", 
          "major mechanism", 
          "expression", 
          "inhibition", 
          "HDAC3", 
          "patients", 
          "tamoxifen", 
          "therapy", 
          "immunohistochemistry", 
          "receptors", 
          "ResultsWe", 
          "blotting", 
          "loss", 
          "treatment", 
          "inhibitors", 
          "viability", 
          "tissue", 
          "proliferation", 
          "resistance", 
          "exposure", 
          "deficiency", 
          "occurrence", 
          "mechanism", 
          "status", 
          "assays", 
          "axis", 
          "ConclusionsFrom", 
          "target", 
          "study", 
          "role", 
          "rate", 
          "reversal", 
          "H3K9", 
          "effect", 
          "cleavage", 
          "samples", 
          "ability", 
          "data", 
          "lines", 
          "stabilization", 
          "approach"
        ], 
        "name": "Endocrine resistant breast cancer cells with loss of ER\u03b1 expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage", 
        "pagination": "65-80", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1122393108"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s13402-019-00439-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31701491"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s13402-019-00439-x", 
          "https://app.dimensions.ai/details/publication/pub.1122393108"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:03", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_811.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s13402-019-00439-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13402-019-00439-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13402-019-00439-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13402-019-00439-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13402-019-00439-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    346 TRIPLES      21 PREDICATES      142 URIs      119 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s13402-019-00439-x schema:about N00c532fbd19b45c3a6f007091cfbfff9
    2 N233b9f6edac64177b20d6d432073eed9
    3 N3cd44b0a0ad74cdaa7296565d0685f54
    4 N5392b1bfbe08458aae262d89f7feca30
    5 N5726713fad3748be90638ef8acaf8deb
    6 N75a1c35f3c1c4c71a2a8879cc93143c0
    7 N7fc77cc3afcb4e56978bef52427abd9f
    8 N8091c618d6a046c78062900ad8012a16
    9 N83de18c3376e402ba0f232892ff4f0d1
    10 N85bc77a39b47490c9b46eb1b659630ae
    11 N8db9c6ce9773457091b02dee5dfa051f
    12 N941c6e1ef76b405fa45122453c8a4b2b
    13 Na863dd7e0c4248db9e67aee2ed5302e4
    14 Nbd964c00482b4e8292fb6eb0fd838acd
    15 Nd3575cf6957b4a6d888755911436f0d4
    16 Need07d4a0eb540f39a301d0a74c71e7e
    17 Nfa2bd770518e4abbafe81603ef1e2c1e
    18 anzsrc-for:11
    19 anzsrc-for:1103
    20 anzsrc-for:1112
    21 schema:author Nd27becbeb23d4dbfa4c7a62ace48fe88
    22 schema:citation sg:pub.10.1007/bf00665801
    23 sg:pub.10.1007/s13402-017-0322-z
    24 sg:pub.10.1038/bjc.2011.156
    25 sg:pub.10.1038/ncomms8390
    26 sg:pub.10.1038/nrc2713
    27 sg:pub.10.1038/nrc3396
    28 sg:pub.10.1038/oncsis.2016.12
    29 sg:pub.10.1038/s41389-018-0107-x
    30 sg:pub.10.1038/sj.onc.1210610
    31 sg:pub.10.1186/1471-2105-10-s1-s24
    32 sg:pub.10.1186/1471-2121-14-32
    33 sg:pub.10.1186/1471-2407-13-215
    34 sg:pub.10.1186/gb-2008-9-9-r139
    35 sg:pub.10.1186/s13058-015-0533-z
    36 schema:datePublished 2019-11-07
    37 schema:datePublishedReg 2019-11-07
    38 schema:description PurposeEndocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ERα)-positive breast cancer. The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ERα is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism.MethodsEndocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues.ResultsWe found that in endocrine resistant breast cancer cells loss of ERα led to HDAC3 stabilization via decreased ERα-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ERα-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ERα expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ERα deficiency. The ERα-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples.ConclusionsFrom our data we conclude that the ERα-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ERα loss.
    39 schema:genre article
    40 schema:isAccessibleForFree false
    41 schema:isPartOf N21a9f359bada4b8c901b8a89e835a0ac
    42 N6fa63b0935b043f880ee4ce74da6a9e0
    43 sg:journal.1372011
    44 schema:keywords CCK-8
    45 ConclusionsFrom
    46 ERα
    47 ERα deficiency
    48 ERα expression
    49 ERα loss
    50 ERα-positive breast cancer
    51 H3K9
    52 HDAC3
    53 HDAC3 inhibition
    54 PurposeEndocrine therapy
    55 Recent studies
    56 ResultsWe
    57 Western blotting
    58 ability
    59 acetylation status
    60 approach
    61 assays
    62 axis
    63 blotting
    64 breast cancer
    65 breast cancer cell lines
    66 breast cancer cells
    67 breast cancer samples
    68 breast cancer tissues
    69 cancer
    70 cancer cell lines
    71 cancer cell loss
    72 cancer cells
    73 cancer samples
    74 cancer tissues
    75 cell lines
    76 cell loss
    77 cells
    78 cleavage
    79 colony forming assays
    80 cure rate
    81 data
    82 deficiency
    83 effect
    84 endocrine resistance
    85 endocrine-resistant breast cancer
    86 endocrine-resistant breast cancer cells
    87 estrogen receptor
    88 exposure
    89 expression
    90 immunohistochemistry
    91 inhibition
    92 inhibition of HDAC3
    93 inhibitors
    94 lines
    95 loss
    96 loss of ERα
    97 mRNA expression
    98 major mechanism
    99 mechanism
    100 molecular mechanisms
    101 occurrence
    102 pan-HDAC inhibitors
    103 patients
    104 positive breast cancer
    105 primary breast cancer tissues
    106 proliferation
    107 proliferative ability
    108 protein expression
    109 qRT-PCR
    110 rate
    111 receptors
    112 resistance
    113 resistant breast cancer
    114 resistant breast cancer cell lines
    115 resistant breast cancer cells
    116 reversal
    117 role
    118 samples
    119 stabilization
    120 status
    121 study
    122 tamoxifen
    123 target
    124 therapeutic target
    125 therapy
    126 tissue
    127 treatment
    128 viability
    129 schema:name Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage
    130 schema:pagination 65-80
    131 schema:productId N54c9617050af4f60885da767ac391516
    132 N557b63b9c19e402683ba9e5ce867b4c0
    133 Na5b238e1303d49719bf3671c7ca8e1d7
    134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122393108
    135 https://doi.org/10.1007/s13402-019-00439-x
    136 schema:sdDatePublished 2022-09-02T16:03
    137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    138 schema:sdPublisher N35d3cdd3882d40bf8a320dd8ecfb5a86
    139 schema:url https://doi.org/10.1007/s13402-019-00439-x
    140 sgo:license sg:explorer/license/
    141 sgo:sdDataset articles
    142 rdf:type schema:ScholarlyArticle
    143 N00c532fbd19b45c3a6f007091cfbfff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Female
    145 rdf:type schema:DefinedTerm
    146 N09bdea659452476fab550df29fe4555b rdf:first Ne0bb045174114ad2b38c650d6ce28f3d
    147 rdf:rest N11b6000774c94a098c0f94fb6389b931
    148 N11b6000774c94a098c0f94fb6389b931 rdf:first sg:person.011111522421.51
    149 rdf:rest N6ef89f18bec64bc59ccc556c9d3a366b
    150 N21a9f359bada4b8c901b8a89e835a0ac schema:volumeNumber 43
    151 rdf:type schema:PublicationVolume
    152 N22db5dd756924044acbeb2ad4e2ad105 rdf:first sg:person.015431126577.07
    153 rdf:rest N09bdea659452476fab550df29fe4555b
    154 N233b9f6edac64177b20d6d432073eed9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Immunohistochemistry
    156 rdf:type schema:DefinedTerm
    157 N35d3cdd3882d40bf8a320dd8ecfb5a86 schema:name Springer Nature - SN SciGraph project
    158 rdf:type schema:Organization
    159 N3cd44b0a0ad74cdaa7296565d0685f54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Cell Line, Tumor
    161 rdf:type schema:DefinedTerm
    162 N4afc5bff8a00476296b15e33ff41b59c rdf:first sg:person.01275503103.89
    163 rdf:rest Ne3bcbf88024b4eb4b95506cf681fd357
    164 N5392b1bfbe08458aae262d89f7feca30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Caspase 7
    166 rdf:type schema:DefinedTerm
    167 N54c9617050af4f60885da767ac391516 schema:name dimensions_id
    168 schema:value pub.1122393108
    169 rdf:type schema:PropertyValue
    170 N557b63b9c19e402683ba9e5ce867b4c0 schema:name pubmed_id
    171 schema:value 31701491
    172 rdf:type schema:PropertyValue
    173 N5726713fad3748be90638ef8acaf8deb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Cell Survival
    175 rdf:type schema:DefinedTerm
    176 N6ef89f18bec64bc59ccc556c9d3a366b rdf:first sg:person.0671022567.52
    177 rdf:rest Nf0ee8f144230460482d6ab913f36cbcb
    178 N6fa63b0935b043f880ee4ce74da6a9e0 schema:issueNumber 1
    179 rdf:type schema:PublicationIssue
    180 N75a1c35f3c1c4c71a2a8879cc93143c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Tamoxifen
    182 rdf:type schema:DefinedTerm
    183 N7fc77cc3afcb4e56978bef52427abd9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Histone Deacetylases
    185 rdf:type schema:DefinedTerm
    186 N8091c618d6a046c78062900ad8012a16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Acetylation
    188 rdf:type schema:DefinedTerm
    189 N83de18c3376e402ba0f232892ff4f0d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Histone Deacetylase Inhibitors
    191 rdf:type schema:DefinedTerm
    192 N85bc77a39b47490c9b46eb1b659630ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Breast Neoplasms
    194 rdf:type schema:DefinedTerm
    195 N8db9c6ce9773457091b02dee5dfa051f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Histones
    197 rdf:type schema:DefinedTerm
    198 N941c6e1ef76b405fa45122453c8a4b2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Cell Proliferation
    200 rdf:type schema:DefinedTerm
    201 Na5b238e1303d49719bf3671c7ca8e1d7 schema:name doi
    202 schema:value 10.1007/s13402-019-00439-x
    203 rdf:type schema:PropertyValue
    204 Na863dd7e0c4248db9e67aee2ed5302e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    205 schema:name Humans
    206 rdf:type schema:DefinedTerm
    207 Nbd964c00482b4e8292fb6eb0fd838acd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    208 schema:name Gene Expression Regulation, Neoplastic
    209 rdf:type schema:DefinedTerm
    210 Nc5f6b622a43945df9226961250754a08 rdf:first sg:person.01000607441.15
    211 rdf:rest Ne79b1c8b11c04b55818bb3389a341b0d
    212 Nd27becbeb23d4dbfa4c7a62ace48fe88 rdf:first sg:person.01230313474.41
    213 rdf:rest Nc5f6b622a43945df9226961250754a08
    214 Nd3575cf6957b4a6d888755911436f0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    215 schema:name RNA Interference
    216 rdf:type schema:DefinedTerm
    217 Ne0bb045174114ad2b38c650d6ce28f3d schema:affiliation grid-institutes:grid.260474.3
    218 schema:familyName Huang
    219 schema:givenName Ling
    220 rdf:type schema:Person
    221 Ne3bcbf88024b4eb4b95506cf681fd357 rdf:first sg:person.0631531742.53
    222 rdf:rest rdf:nil
    223 Ne79b1c8b11c04b55818bb3389a341b0d rdf:first sg:person.015756424740.95
    224 rdf:rest N22db5dd756924044acbeb2ad4e2ad105
    225 Need07d4a0eb540f39a301d0a74c71e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Drug Resistance, Neoplasm
    227 rdf:type schema:DefinedTerm
    228 Nf0ee8f144230460482d6ab913f36cbcb rdf:first sg:person.016170133655.63
    229 rdf:rest N4afc5bff8a00476296b15e33ff41b59c
    230 Nfa2bd770518e4abbafe81603ef1e2c1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    231 schema:name Estrogen Receptor alpha
    232 rdf:type schema:DefinedTerm
    233 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    234 schema:name Medical and Health Sciences
    235 rdf:type schema:DefinedTerm
    236 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    237 schema:name Clinical Sciences
    238 rdf:type schema:DefinedTerm
    239 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    240 schema:name Oncology and Carcinogenesis
    241 rdf:type schema:DefinedTerm
    242 sg:grant.8351548 http://pending.schema.org/fundedItem sg:pub.10.1007/s13402-019-00439-x
    243 rdf:type schema:MonetaryGrant
    244 sg:grant.8370866 http://pending.schema.org/fundedItem sg:pub.10.1007/s13402-019-00439-x
    245 rdf:type schema:MonetaryGrant
    246 sg:journal.1372011 schema:issn 2211-3428
    247 2211-3436
    248 schema:name Cellular Oncology
    249 schema:publisher Springer Nature
    250 rdf:type schema:Periodical
    251 sg:person.01000607441.15 schema:affiliation grid-institutes:grid.260474.3
    252 schema:familyName Gong
    253 schema:givenName Xue
    254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000607441.15
    255 rdf:type schema:Person
    256 sg:person.011111522421.51 schema:affiliation grid-institutes:grid.260474.3
    257 schema:familyName Zhang
    258 schema:givenName Jun
    259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011111522421.51
    260 rdf:type schema:Person
    261 sg:person.01230313474.41 schema:affiliation grid-institutes:grid.260474.3
    262 schema:familyName Yu
    263 schema:givenName Shiyi
    264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230313474.41
    265 rdf:type schema:Person
    266 sg:person.01275503103.89 schema:affiliation grid-institutes:None
    267 schema:familyName Yu
    268 schema:givenName Zhenghong
    269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275503103.89
    270 rdf:type schema:Person
    271 sg:person.015431126577.07 schema:affiliation grid-institutes:grid.260474.3
    272 schema:familyName Zhang
    273 schema:givenName Meng
    274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015431126577.07
    275 rdf:type schema:Person
    276 sg:person.015756424740.95 schema:affiliation grid-institutes:grid.260474.3
    277 schema:familyName Ma
    278 schema:givenName Zhifang
    279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015756424740.95
    280 rdf:type schema:Person
    281 sg:person.016170133655.63 schema:affiliation grid-institutes:grid.59053.3a
    282 schema:familyName Zhu
    283 schema:givenName Tao
    284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016170133655.63
    285 rdf:type schema:Person
    286 sg:person.0631531742.53 schema:affiliation grid-institutes:grid.260474.3
    287 schema:familyName Chen
    288 schema:givenName Liming
    289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631531742.53
    290 rdf:type schema:Person
    291 sg:person.0671022567.52 schema:affiliation grid-institutes:None
    292 schema:familyName Zhao
    293 schema:givenName Shuang
    294 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671022567.52
    295 rdf:type schema:Person
    296 sg:pub.10.1007/bf00665801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030257873
    297 https://doi.org/10.1007/bf00665801
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1007/s13402-017-0322-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1084037136
    300 https://doi.org/10.1007/s13402-017-0322-z
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1038/bjc.2011.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040609384
    303 https://doi.org/10.1038/bjc.2011.156
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1038/ncomms8390 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019679615
    306 https://doi.org/10.1038/ncomms8390
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1038/nrc2713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018166274
    309 https://doi.org/10.1038/nrc2713
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1038/nrc3396 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031306051
    312 https://doi.org/10.1038/nrc3396
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1038/oncsis.2016.12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014215205
    315 https://doi.org/10.1038/oncsis.2016.12
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.1038/s41389-018-0107-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1110807996
    318 https://doi.org/10.1038/s41389-018-0107-x
    319 rdf:type schema:CreativeWork
    320 sg:pub.10.1038/sj.onc.1210610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023418889
    321 https://doi.org/10.1038/sj.onc.1210610
    322 rdf:type schema:CreativeWork
    323 sg:pub.10.1186/1471-2105-10-s1-s24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013766507
    324 https://doi.org/10.1186/1471-2105-10-s1-s24
    325 rdf:type schema:CreativeWork
    326 sg:pub.10.1186/1471-2121-14-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008132874
    327 https://doi.org/10.1186/1471-2121-14-32
    328 rdf:type schema:CreativeWork
    329 sg:pub.10.1186/1471-2407-13-215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004045936
    330 https://doi.org/10.1186/1471-2407-13-215
    331 rdf:type schema:CreativeWork
    332 sg:pub.10.1186/gb-2008-9-9-r139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048888907
    333 https://doi.org/10.1186/gb-2008-9-9-r139
    334 rdf:type schema:CreativeWork
    335 sg:pub.10.1186/s13058-015-0533-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1049624305
    336 https://doi.org/10.1186/s13058-015-0533-z
    337 rdf:type schema:CreativeWork
    338 grid-institutes:None schema:alternateName Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People’s Republic of China
    339 schema:name Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, People’s Republic of China
    340 rdf:type schema:Organization
    341 grid-institutes:grid.260474.3 schema:alternateName Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People’s Republic of China
    342 schema:name Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, 210023, Nanjing, People’s Republic of China
    343 rdf:type schema:Organization
    344 grid-institutes:grid.59053.3a schema:alternateName Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, 230027, Hefei, People’s Republic of China
    345 schema:name Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, 230027, Hefei, People’s Republic of China
    346 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...